Ambalal Sarabhai Enterprises Ltd
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
- Market Cap ₹ 349 Cr.
- Current Price ₹ 45.5
- High / Low ₹ 70.0 / 20.0
- Stock P/E 121
- Book Value ₹ 16.6
- Dividend Yield 0.00 %
- ROCE 11.1 %
- ROE 8.99 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 6.36% over past five years.
- Promoter holding is low: 30.8%
- Earnings include an other income of Rs.11.2 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
89 | 100 | 105 | 124 | 132 | 134 | 125 | 150 | 133 | 163 | 197 | 170 | 164 | |
112 | 111 | 112 | 129 | 145 | 137 | 137 | 144 | 136 | 165 | 171 | 162 | 161 | |
Operating Profit | -24 | -10 | -7 | -4 | -13 | -3 | -12 | 6 | -3 | -2 | 25 | 8 | 3 |
OPM % | -26% | -10% | -7% | -3% | -10% | -2% | -9% | 4% | -2% | -1% | 13% | 5% | 2% |
26 | 16 | 2 | 13 | 95 | -2 | 25 | 8 | 24 | 40 | 33 | 12 | 11 | |
Interest | 10 | 9 | 11 | 10 | 4 | 5 | 3 | 3 | 4 | 3 | 2 | 3 | 4 |
Depreciation | 3 | 14 | 3 | 5 | 17 | 4 | 2 | 2 | 3 | 2 | 2 | 3 | 4 |
Profit before tax | -10 | -16 | -20 | -6 | 62 | -14 | 8 | 8 | 15 | 33 | 54 | 15 | 6 |
Tax % | -11% | -11% | -3% | -13% | 22% | -34% | 84% | 48% | 6% | 10% | 13% | 25% | |
-11 | -18 | -20 | -7 | 48 | -18 | 1 | 4 | 14 | 29 | 47 | 11 | 3 | |
EPS in Rs | -1.40 | -2.39 | -2.64 | -0.87 | 6.28 | -2.38 | 0.17 | 0.55 | 1.83 | 3.83 | 6.16 | 1.45 | 0.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 6% |
3 Years: | 9% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 27% |
3 Years: | -7% |
TTM: | -78% |
Stock Price CAGR | |
---|---|
10 Years: | 34% |
5 Years: | 26% |
3 Years: | 38% |
1 Year: | 119% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 21% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
Reserves | -40 | -59 | -79 | -86 | -38 | -51 | -50 | -46 | -32 | -3 | 43 | 54 | 50 |
29 | 39 | 42 | 46 | 47 | 42 | 43 | 40 | 31 | 28 | 27 | 42 | 44 | |
114 | 110 | 128 | 132 | 94 | 93 | 128 | 144 | 111 | 108 | 84 | 73 | 69 | |
Total Liabilities | 180 | 167 | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 240 |
111 | 98 | 94 | 91 | 72 | 72 | 59 | 58 | 57 | 57 | 58 | 85 | 89 | |
CWIP | 0 | 0 | 0 | 1 | 9 | 3 | 14 | 24 | 0 | 1 | 12 | 4 | 0 |
Investments | 2 | 1 | 1 | 1 | 8 | 5 | 5 | 9 | 18 | 27 | 33 | 32 | 31 |
66 | 67 | 71 | 76 | 92 | 80 | 119 | 123 | 110 | 125 | 128 | 125 | 121 | |
Total Assets | 180 | 167 | 167 | 169 | 180 | 160 | 197 | 214 | 186 | 210 | 231 | 246 | 240 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-13 | -3 | 11 | -8 | -75 | 5 | -7 | 19 | -7 | -2 | 11 | 6 | |
11 | -0 | -1 | 10 | 80 | -3 | 18 | -9 | 17 | 10 | 5 | -17 | |
1 | 3 | -8 | -1 | -3 | -6 | -2 | -6 | -14 | -6 | -19 | 9 | |
Net Cash Flow | -1 | -1 | 2 | 1 | 2 | -4 | 8 | 3 | -4 | 2 | -3 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 90 | 101 | 95 | 74 | 83 | 79 | 100 | 84 | 79 | 87 | 52 | 58 |
Inventory Days | 86 | 92 | 95 | 86 | 72 | 66 | 75 | 61 | 76 | 58 | 48 | 62 |
Days Payable | 236 | 142 | 178 | 139 | 135 | 138 | 207 | 191 | 184 | 184 | 151 | 131 |
Cash Conversion Cycle | -60 | 51 | 12 | 22 | 20 | 6 | -32 | -46 | -29 | -39 | -50 | -11 |
Working Capital Days | -226 | -161 | -219 | -204 | -47 | -89 | -98 | -120 | -74 | -37 | 18 | 35 |
ROCE % | -17% | -14% | -16% | -19% | -44% | -1% | -5% | 16% | 25% | 18% | 34% | 11% |
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 20h
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 20h
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 21 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Feb - Company has completed the process of dispatch of Postal Ballot Notice through electronic mode and in Compliance with Regulation 30 please find enclosed Newspaper cuttings …
- Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 23 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad